Yelena V Kovtun

Summary

Affiliation: ImmunoGen Inc
Country: USA

Publications

  1. ncbi request reprint Antibody-drug conjugates designed to eradicate tumors with homogeneous and heterogeneous expression of the target antigen
    Yelena V Kovtun
    ImmunoGen, Inc, Cambridge, Massachusetts 02139, USA
    Cancer Res 66:3214-21. 2006
  2. ncbi request reprint Cell killing by antibody-drug conjugates
    Yelena V Kovtun
    ImmunoGen Inc, 128 Sidney Street, Cambridge, MA 02139 4239, USA
    Cancer Lett 255:232-40. 2007
  3. doi request reprint Antibody-maytansinoid conjugates designed to bypass multidrug resistance
    Yelena V Kovtun
    ImmunoGen, Inc, Waltham, Massachusetts 02451, USA
    Cancer Res 70:2528-37. 2010
  4. ncbi request reprint Antibody-maytansinoid conjugates are activated in targeted cancer cells by lysosomal degradation and linker-dependent intracellular processing
    Hans K Erickson
    ImmunoGen, Inc, Cambridge, Massachusetts 02139, USA
    Cancer Res 66:4426-33. 2006
  5. ncbi request reprint Antibody-drug conjugates: using monoclonal antibodies for delivery of cytotoxic payloads to cancer cells
    Victor S Goldmacher
    ImmunoGen, Inc, 830 Winter Street, Waltham, MA 02451 1477, USA
    Ther Deliv 2:397-416. 2011
  6. pmc High-affinity accumulation of a maytansinoid in cells via weak tubulin interaction
    Victor S Goldmacher
    Department of Cell Biology, ImmunoGen, Inc, Waltham, Massachusetts, United States of America
    PLoS ONE 10:e0117523. 2015
  7. doi request reprint A New Triglycyl Peptide Linker for Antibody-Drug Conjugates (ADCs) with Improved Targeted Killing of Cancer Cells
    Rajeeva Singh
    ImmunoGen, Inc, Waltham, Massachusetts
    Mol Cancer Ther 15:1311-20. 2016

Collaborators

Detail Information

Publications7

  1. ncbi request reprint Antibody-drug conjugates designed to eradicate tumors with homogeneous and heterogeneous expression of the target antigen
    Yelena V Kovtun
    ImmunoGen, Inc, Cambridge, Massachusetts 02139, USA
    Cancer Res 66:3214-21. 2006
    ..Our data offer a rationale for developing optimally constructed antibody-drug conjugates for treating tumors that express the target antigen either in a homogeneous or heterogeneous manner...
  2. ncbi request reprint Cell killing by antibody-drug conjugates
    Yelena V Kovtun
    ImmunoGen Inc, 128 Sidney Street, Cambridge, MA 02139 4239, USA
    Cancer Lett 255:232-40. 2007
    ..This review summarizes the current knowledge of the mechanisms of killing of antigen-expressing and bystander cells by antibody-drug conjugates...
  3. doi request reprint Antibody-maytansinoid conjugates designed to bypass multidrug resistance
    Yelena V Kovtun
    ImmunoGen, Inc, Waltham, Massachusetts 02451, USA
    Cancer Res 70:2528-37. 2010
    ..This study points the way to the development of ADCs that bypass multidrug resistance...
  4. ncbi request reprint Antibody-maytansinoid conjugates are activated in targeted cancer cells by lysosomal degradation and linker-dependent intracellular processing
    Hans K Erickson
    ImmunoGen, Inc, Cambridge, Massachusetts 02139, USA
    Cancer Res 66:4426-33. 2006
    ....
  5. ncbi request reprint Antibody-drug conjugates: using monoclonal antibodies for delivery of cytotoxic payloads to cancer cells
    Victor S Goldmacher
    ImmunoGen, Inc, 830 Winter Street, Waltham, MA 02451 1477, USA
    Ther Deliv 2:397-416. 2011
    ..In this article, we will review the considerations for selecting a target antigen, the design of the conjugate, and the pre-clinical and clinical experiences with the current generation of antibody-drug conjugates...
  6. pmc High-affinity accumulation of a maytansinoid in cells via weak tubulin interaction
    Victor S Goldmacher
    Department of Cell Biology, ImmunoGen, Inc, Waltham, Massachusetts, United States of America
    PLoS ONE 10:e0117523. 2015
    ..As a result, a significant fraction of microtubule tips is occupied with a maytansinoid when added to cells at sub-nanomolar concentrations, inducing mitotic arrest and cell death...
  7. doi request reprint A New Triglycyl Peptide Linker for Antibody-Drug Conjugates (ADCs) with Improved Targeted Killing of Cancer Cells
    Rajeeva Singh
    ImmunoGen, Inc, Waltham, Massachusetts
    Mol Cancer Ther 15:1311-20. 2016
    ..Overall, these data suggest that CX represents a promising linker option for the development of ADCs with improved therapeutic properties. Mol Cancer Ther; 15(6); 1311-20. ©2016 AACR. ..